离子通道阻滞剂抗结核作用的研究进展

doi:10.20047/j.issn1673-7210.2023.17.12

Abstract
Figure/Table
References (30)
Related Citation (12)

Download: PDF (527 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Tuberculosis is a global public health disease caused by Mycobacterium tuberculosis (MTB) infection. The treatment of tuberculosis requires long-term use of multiple drugs, and becomes complicated and lengthy due to compliance and drug resistance. The sensitivity of MTB to drugs is to some extent determined by the interaction between bacteria and host macrophages. MTB mainly exists in macrophages after infecting the human body, and by inhibiting the physiological activity of macrophages, the body is in an infected state. Ion channel blockers regulate the concentration of signaling ions in macrophages by affecting the activity of ion channels, enhance the killing effect of host macrophages on MTB, and inhibit the activity of MTB efflux pumps, and improve the sensitivity of MTB to drugs. This article reviews some effective ion channel blockers for MTB and preliminarily explores their anti-tuberculosis mechanisms, hoping to provide new ideas for the development of new anti-tuberculosis drugs.

Key words： Ion channel blockers Mycobacterium tuberculosis Tuberculosis drug Macrophages

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LUO Shuiqing1 ZENG Yali2

Cite this article:

LUO Shuiqing1 ZENG Yali2. Research progress on anti-tuberculosis effect of ion channel blockers[J]. 中国医药导报, 2023, 20(17): 57-60.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.17.12 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I17/57

[1] Kondratskyi A，Kondratska K，Skryma R，et al. Ion channels in the regulation of autophagy [J]. Autophagy，2018，14（1）：3-21.
[2] Zhang R，Kang R，Klionsky DJ，et al. Ion channels and transporters in autophagy [J]. Autophagy，2022，18（1）：4-23.
[3] Kendall RL，Holian A. The role of lysosomal ion channels in lysosome dysfunction [J]. Inhal Toxicol，2021，33（2）：41-54.
[4] 罗微，王倩，袁纯辉.结核分枝杆菌逃逸巨噬细胞杀伤机制的研究进展[J].中华微生物学和免疫学杂志，2020，40（11）：876-882.
[5] Geneva：World Health Organization，Global tuberculosis report 2021[M]. Licence：CC BY-NC-SA 3.0 IGO，2021.
[6] Hogan AB，Jewell BL，Sherrard-Smith E，et al. Potential impact of the COVID-19 pandemic on HIV，tuberculosis，and malaria in low-income and middle-income countries：a mod- elling study [J]. Lancet Glob Health，2020，8（9）：e1132- e1141.
[7] Daniel C，Bhakta S. Immunobiology of tubercle bacilli and prospects of immunomodulatory drugs to tackle tuberculosis （TB） and other non-tubercular mycobacterial infections [J]. Immunobiology，2022，227（3）：152224.
[8] Mitini-Nkhoma SC，Chimbayo ET，Mzinza DT，et al. Something old，something new：ion channel blockers as potential anti-tuberculosis agents [J]. Front Immunol，2021，12：665785.
[9] Malek M，Haucke V. Inositol triphosphate signaling triggers lysosome biogenesis via calcium release from endoplasmic reticulum stores [J]. Contact（Thousand Oaks），2022，5：2515 25642210970.
[10] Abuammar H，Bhattacharjee A，Simon-Vecsei Z，et al. Ion channels and pumps in autophagy：a reciprocal relationship [J]. Cells，2021，10（12）：3537.
[11] Germic N，Frangez Z，Yousefi S，et al. Regulation of the innate immune system by autophagy：monocytes，macropha- ges，dendritic cells and antigen presentation [J]. Cell Death Differ，2019，26（4）：715-727.
[12] Kusner DJ，Barton JA. ATP stimulates human macrophages to kill intracellular virulent Mycobacterium tuberculosis via calcium-dependent phagosome-lysosome fusion [J]. J Immunol，2001，167（6）：3308-3315.
[13] Feske S，Wulff H，Skolnik EY. Ion channels in innate and adaptive immunity [J]. Annu Rev Immunol，2015，33：291- 353.
[14] Lee CC，Lee MG，Hsu WT，et al. Use of calcium channel blockers and risk of active tuberculosis disease： a population-based analysis [J]. Hypertension，2021，77（2）：328- 337.
[15] Singh A，Anang V，Kumar Rana A，et al. Deciphering the role of calcium homeostasis in T cells functions during mycobacterial infection [J]. Cell Immunol，2020，357：104198.
[16] Paik S，Kim JK，Chung C，et al. Autophagy：a new strategy for host-directed therapy of tuberculosis [J]. Virulence，2019，10（1）：448-459.
[17] Chen C，Gardete S，Jansen RS，et al. Verapamil targets membrane energetics in Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother，2018，62（5）：e02107-e02117.
[18] Mitini-Nkhoma SC，Fernando N，Ishaka GKD，et al. Ion tr- ansport modulators as antimycobacterial agents [J]. Tuberc Res Treat，2020，2020：3767915.
[19] Amaral L，Viveiros M. Thioridazine：a non-antibiotic drug highly effective，in combination with first line anti-tuberculosis drugs，against any form of antibiotic resistance of mycobacterium tuberculosis due to its multi-mechanisms of action [J]. Antibiotics （Basel），2017，6（1）：3.
[20] Nizi MG，Desantis J，Nakatani Y，et al. Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors [J]. Eur J Med Chem，2020， 201：112420.
[21] Omollo C，Singh V，Kigondu E，et al. Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother，2023，65（5）：e02554-20.
[22] Martins M，Viveiros M，Amaral L. Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages [J]. In Vivo，2008，22（1）：69-75.
[23] Kazama I. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19：can it be a novel therapeutic strategy? [J]. Drug Discov Ther，2020，14（3）：143-144.
[24] Mishra R，Kohli S，Malhotra N，et al. Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis [J]. Sci Transl Med，2019，11（518）： eaaw6635.
[25] Matt U，Selchow P，Dal Molin M，et al. Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux [J]. Int J Antimicrob Agents，2017，50（1）：55-62.
[26] Te Brake LHM，De Knegt GJ，De Steenwinkel JE，et al. The role of efflux pumps in tuberculosis treatment and their pro- mise as a target in drug development：unraveling the black box [J]. Annu Rev Pharmacol Toxicol，2018，58：271-291.
[27] Choi SW，Gu Y，Peters RS，et al. Ambroxol induces autop- hagy and potentiates rifampin antimycobacterial activity [J]. Antimicrob Agents Chemother，2018，62（9）：e01019- 010118.
[28] Sun H，Jiang J，Gong L，et al. Voltage-gated sodium channel inhibitor reduces atherosclerosis by modulating monocyte/macrophage subsets and suppressing macrophage proliferation [J]. Biomed Pharmacother，2019，120：109352.
[29] McNeill J，Rudyk C，Hildebrand ME，et al. Ion channels and electrophysiological properties of astrocytes：implications for emergent stimulation technologies [J]. Front Cell Neurosci，2021，15：644126.
[30] Kawai T，Kayama K，Tatsumi S，et al. Regulation of hepatic oxidative stress by voltage-gated proton channels （Hv1/ VSOP） in Kupffer cells and its potential relationship with glucose metabolism [J]. FASEB J，2020，34（12）：15805- 15821.